Poly ADP-ribose polymerase inhibitors (PARPi) are used for patients with advanced prostate cancer bearing alterations in homologous recombination repair (HRR) genes. We sought to characterize HRR gene ...
New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...
DNA damage agents constantly target the genome integrity causing lethal damages. Homologous DNA repair as universal error-free repair pathway constitutively acts to remove double strand breaks. Tumour ...
DNA double-strand breaks (DSBs) induced by ionizing radiation pose a major threat to cell survival. The cell can respond to the presence of DSBs through two major repair pathways: homologous ...
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous ...
Tokyo, Japan – Researchers from Tokyo Metropolitan University have been studying DNA repair by homologous recombination, where the RecA protein repairs breaks in double-stranded DNA by incorporating a ...
A recent study, undertaken by researchers at the Tokyo Metropolitan University and the Tokyo Metropolitan Institute of Medical Science (both Japan), unravels key steps in the process of homologous ...
The discovery of synthetic lethality between BRCA mutations and PARP inhibitors ranks has led to major advances in the treatment of BRCA-mutated cancers. Mutations in BRCA1 and BRCA2 can leave cells ...
Scientists have created a blood test to guide more effective ovarian cancer treatment, by identifying the women more likely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback